<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Live-attenuated varicella vaccine is effective and safe in immunocompetent children </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we assess the immunogenicity and adverse events following varicella vaccination in immunosuppressed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> children </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:e sem="disease" ids="C0740380" disease_type="Disease or Syndrome" abbrv="">Varicella-zoster</z:e> virus (VZV)-seronegative <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> children received two doses of live-attenuated VZV vaccine (Varilrix) in a span of 3 months </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (ALL) were in the maintenance phase of chemotherapy, whereas those with <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> joined the study around 3-6 months from treatment discontinuation </plain></SENT>
<SENT sid="4" pm="."><plain>VZV-specific cellular and humoral immune responses were measured before and after VZV vaccination </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The median (range) age of the 17 patients was 4.4 yr (2.0-14.5) </plain></SENT>
<SENT sid="6" pm="."><plain>Thirteen had ALL, one had <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and three had <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Following vaccination, the VZV-specific stimulation index (SI) increased from 1.7 (0.9-2.9) to 17.9 (5.9-36.0) (P &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Similarly, SI to phytohaemagglutinin <z:chebi fb="0" ids="52290">mitogen</z:chebi> increased from 1136 (499-1930) to 1714 (848-2518) (P = 0.028) </plain></SENT>
<SENT sid="9" pm="."><plain>There were also significant increases in CD4+ cells and CD4:CD8 ratio as well as a reduction in CD16/56+ cells in peripheral blood lymphocytes </plain></SENT>
<SENT sid="10" pm="."><plain>Seroconversion rate to VZV was 19% after one dose and increased to 94% after the second dose of VZV vaccine </plain></SENT>
<SENT sid="11" pm="."><plain>Serum VZV-specific IgG concentrations also increased significantly following two doses when compared with one dose of VZV vaccine (P = 0.0004) </plain></SENT>
<SENT sid="12" pm="."><plain>One subject developed possibly vaccine-related <z:e sem="disease" ids="C0008049" disease_type="Disease or Syndrome" abbrv="">chickenpox</z:e> with self-limiting <z:hpo ids='HP_0012115'>hepatitis</z:hpo> at 5 wk following vaccination </plain></SENT>
<SENT sid="13" pm="."><plain>None of the patients developed <z:e sem="disease" ids="C0019360" disease_type="Disease or Syndrome" abbrv="ZONA">herpes-zoster</z:e> at a median (range) follow-up of 27.5 months (24.0-30.0) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: Non-immune <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> children can be effectively vaccinated against <z:e sem="disease" ids="C0008049" disease_type="Disease or Syndrome" abbrv="">chickenpox</z:e> at the defined period </plain></SENT>
<SENT sid="15" pm="."><plain>However, the safety of <z:e sem="disease" ids="C0008049" disease_type="Disease or Syndrome" abbrv="">chickenpox</z:e> vaccine in these immunosuppressed children needs to be further studied </plain></SENT>
</text></document>